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Abstract: Dynamic contrast-enhanced magnetic resonance imaging has been recently 
shown to be effective for diagnostic urography. High-resolution urographic images can be 
acquired with T1 contrast agents for the kidney and urinary tract with minimal noise in the 
abdomen. Currently, clinical contrast agents are low molecular weight agents and can rapidly 
extravasate from blood circulation, leading to slow contrast agent elimination through kidney 
and consequently providing limited contrast enhancement in urinary tract. In this study, a new 
biodegradable macromolecular contrast agent, nanoglobule-G4-cystamine-(Gd-DO3A), was 
prepared by conjugating Gd-DO3A chelates on the surface of a generation 4 nanoglobule, 
poly-l-lysine octa(3-aminopropyl)silsesquioxane dendrimer, via a disulfide spacer, where the 
carrier had a precisely defined nanosize that is far smaller than the renal filtration threshold. 
The in vivo contrast enhancement and dynamic imaging of the urinary tract of the agent was 
evaluated in nude mice using a low molecular weight agent Gd(DTPA-BMA) as a control. The 
agent eliminated rapidly from blood circulation and accumulated more abundantly in urinary 
tract than Gd(DTPA-BMA). The fast elimination kinetics is ideal for functional evaluation 
of the kidneys. The morphology of the kidneys and urinary tract was better visualized by the 
biodegradable nanoglobular contrast agent than Gd(DTPA-BMA). The agent also resulted in 
low liver contrast enhancement, indicating low nonspecific tissue deposition. These features 
render the G4 nanoglobule-cystamine-(Gd-DO3A) conjugate a promising contrast agent for 
magnetic resonance urography.
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Introduction
Morphological and functional imaging of the kidneys and urinary tract is crucial for 
accurate diagnosis of diseases in the urinary system and for better therapeutic decisions 
to treat patients with urological disorders. Ultrasonography and computed tomography 
(CT) are the commonly used diagnostic modalities for morphological imaging of the 
urinary system.1–4 CT with a large dose of iodinated contrast agents and diuretic renal 
scintigraphy using radioactive probes containing Tc-99m are often used for functional 
renal imaging.5–7 However, these modalities provide limited information for accurate 
diagnosis due to poor image qualities. Magnetic resonance (MR) urography produces 
morphological images with excellent spatial and contrast resolution.8–10 However, 
the fluid in the abdomen severely interferes the imaging contrast in the ureter and the 
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magnetic resonance imaging (MRI) using   gadolinium-based 
contrast agents can improve the contrast enhancement in the 
urinary tract with minimized interference from the fluid in the 
abdomen.11–15 Meanwhile, the time course of signal intensity 
generated by the contrast agents in DCE MRI can be corre-
lated to the excretory function of the kidneys.16–20 Currently, 
clinical contrast agents are low molecular weight molecules 
and extravasate rapidly from blood circulation and distribute 
throughout the extracellular space of surrounding tissues.21 
Consequently, their rapid extravasation slows down the renal 
excretory rate leading to unfavorable pharmacokinetics in 
the urinary systems.
Macromolecular contrast agents, eg, gadolinium-bound 
albumin, were tested in MRI of urinary system.22 These 
agents have a long blood circulation suitable for kidney 
angiography. However, they are not suitable for urography 
because their renal excretion is limited by their large hydro-
dynamic size. Dendrimers are the macromolecules with 
defined structures and sizes and have been used to develop 
MRI contrast agents with different sizes. For example, 
poly-amidoamine (PAMAM)-based Gd(III) complexes 
have shown size-  dependent pharmacokinetics and renal 
filtration.23 However, the PAMAM-based agents with the 
positively charged cores are associated with high acute 
systemic toxicity.24 In our previous study, a series of nano-
glubular dendrimers, poly-l-lysine octa(3-aminopropyl)
silsesquioxane (OAS) dendrimers, were developed, which 
displayed 3-dimensional (3D) symmetric structures, single 
molecular weight distributions, and low cytotoxicity.25 The 
nanoglobule-based MRI contrast agents showed relatively 
rapid renal filtration and low liver uptake,26 indicating the 
nanoglobular dendrimers as suitable carriers for urographic 
contrast agents.
In this study, we report the preparation and in vivo 
evaluation of a generation 4 (G4) nanoglobule-cystamine-   
(Gd-DO3A) conjugate as an extracellular degradable nano-
sized contrast agent for DCE-MR urography. A disulfide 
spacer (–SS–) was introduced to accelerate the renal excretion 
of gadolinium chelates by reducing the disulfide spacer with 
the free endogenous thiols, including cysteine, glutathione 
(GSH), cysteinylglycine (Cys–Gly), and homocysteine in 
plasma.24,27–29 Since the concentration of thiols is relatively 
low (approximately 50 µM in mice), the spacer is gradually 
reduced in the circulation. The stable Gd-DO3A chelates 
released from the biodegradable nanoglobular contrast 
agent can rapidly transit through renal filtration and accu-
mulate in the urinary tract with sufficient concentration 
for effective DCE-MR urography. The efficacy of the 
G4   nanoglobule-cystamine-(Gd-DO3A) conjugate for 
dynamic MRI of the urinary tract was evaluated in nude 
mice using a low molecular weight agent Gd(DTPA-BMA) 
as a control.
Materials and methods
Materials
Gadolinium acetate (Alfa Aesar, Ward Hill, MA), eth-
ylenediaminetetraacetic acid (EDTA) dipotassium salt 
(Sigma-Aldrich, St. Louis, MO), Gd(DTPA-BMA; GE 
Healthcare, Amersham, UK), Spectra/Por 6 dialysis mem-
brane   (molecular weight cutoff 2 kDa; Spectrum   Laboratories, 
Rancho Dominguez, CA, USA) were used as purchased. 
The G4 nanoglobule, G4 poly-l-lysine OAS dendrimer, 
was prepared according to a reported procedure.25 1,4,7,10-
Tetraazacyclododecane-1,4,7-tris-(acetic acid)-10-(acetic 
acid isothiocyanatocystamine monoamide) (DO3A-SS-NCS) 
was synthesized according to a reported method.24,30 The nu/nu 
mice were purchased from the NCI (Frederick, MD) and were 
cared under an animal protocol approved by the University of 
Utah Institutional Animal Care and Use Committee.
Synthesis procedure
The G4 poly-l-lysine OAS dendrimer was dissolved in water 
at a concentration of 10 mg/mL. DO3A-SS-NCS (128 molar 
excess) was then added into the solution with pH adjusted to 
9 by 1.0 M NaOH. The reaction mixture was stirred at room 
temperature (25°C) for 24 hours. Another 128 molar excess of 
DO3A-SS-NCS was added to the mixture, which was stirred for 
additional 24 hours. The product, G4 nanogobule-  cystamine-
DO3A conjugate, was purified by dialysis against deionized 
water for 48 hours and colorless solid was obtained after 
lyophilization. The nanoglobular ligand was then complexed 
with a 512-fold excess of Gd(OAc)3 based on the amount of 
nanoglobular conjugate in citric acid buffer (pH 5) for 72 hours 
at room temperature. EDTA was added to the mixture, which 
was stirred for additional 1 hour to remove free Gd(III) ions 
associated with the conjugate. The mixture was dialyzed against 
deionized water for 48 hours. The final product was obtained 
after lyophilization. The gadolinium contents in the conjugates 
were measured by inductively coupled plasma optical emis-
sion spectroscopy (ICP-OES; Perkin-Elmer Optima 3100XL, 
Norwalk, CT) at 342 nm. The size of the contrast agent was 
estimated by dynamic light scattering.
Relaxivities
The T1 relaxation time was measured using a standard 
inversion recovery-prepared turbo spin echo sequence on a International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Siemens Trio 3T MRI scanner at room temperature. Three 
different concentrations of each sample were prepared in 
triplicate and placed inside a birdcage human head coil 
and scanned with a series of inversion times (TIs) from 
22 ms to 1,600 ms. The net magnetization (MTI) at each 
TI was calculated from the region of interest (ROI) using 
Osirix (http://www.osirix-viewer.com) software. T1 relax-
ation time was calculated by nonlinear regression fitting of 
Equation 1:
 M TI = M0(1−2exp(−TI/T1))  (1)
where MTI is the net magnetization at time TI; TI is the inver-
sion time; M0 is the initial magnetization. Relaxivity r1 was 
determined as the slope of the plot of 1/T1 vs [Gd3+].
MR imaging
The MRI contrast enhancement of the biodegradable nano-
globular agent was evaluated in female nu/nu mice. The mice 
(10–12 weeks, 25–30 g) were anesthetized by intraperitoneal 
administration of a mixture of xylazine (12 mg/kg) and 
  ketamine (80 mg/kg). The biodegradable nanoglobular con-
trast agent was administered intravenously through a tail vein 
at a dose of 0.033 mMol Gd/kg, whereas Gd(DTPA-BMA) 
was injected at a dose of 0.1 mMol Gd/kg. Three mice were 
used for each agent. The mice were placed in a wrist coil and 
the MR images were acquired before and 2, 5, 10, 15 minutes 
after administration of the contrast agents on a Siemens Trio 
3T scanner. A 3D-FLASH pulse sequence was used to acquire 
whole body images. The parameters of 3D-FLASH sequence 
were 2.74 ms echo time, 7.75 ms repetition time, 25 flip angle, 
120 mM field of view, and 0.4 mM coronal slice thickness. 
MR images were analyzed with Osirix (http://homepage.
mac.com/rossetantoine/osirix/) software. The ROIs in each 
mouse were set at the left ventricle of the heart, liver, and 
bladder. The contrast to noise ratio (CNR) was calculated by 
the   equation: CNR = (SPost − SPre)/((δpost + δpre)/2), where SPost 
and SPre represent the mean signal intensities at the ROI before 
and after administration of contrast agents, and the δpost and 
δpre are the standard deviation of background noises before 
and after contrast agent administration.
Student’s t-test was performed with Prism software 
  (GraphPad Software, San Diego, CA), with significance 
level set at P , 0.05.
Results
The G4 nanoglobule has 4 layers of lysine residues rooted 
from each of the amine groups at the 8 corners of the cubic 
OAS core. It has a compact and relatively symmetric 
3D molecular architecture and is a suitable carrier for mac-
romolecular MRI contrast agent with a precisely defined 
structure.25 The mass (m/z) of the G4 nanoglobule was 16,314 
as determined by MALDI-TOF mass spectrometry, slightly 
greater than the calculated mass (16,263) possibly due to the 
incorporation of solvent molecules in the structure.25 The 
synthesis of the G4 nanoglobular contrast agent is described 
in Scheme 1. The gadolinium(III) content in nanoglobule-
G4-cystamine-(Gd-DO3A) is 0.742 mMol/g with a conju-
gation degree of 18.0%. The calculated molecular weight 
of the nanoglobular contrast agent was 33287.96 Da based 
on the measured Gd(III) contents in the agent. The size of 
the agent was approximately 6.0 nm as determined by light 
scattering. The T1 relaxivity of the agent was 5.5 mM−1 s−1 
at 3 T (Figure 1).
The DCE-MR urography was evaluated in female nude 
mice. Figure 2 shows the 2-dimensional (2D) coronal 
images crossing the heart and bladder before contrast 
and at various time points after contrast for nanoglobule-
G4-cystamine-(Gd-DO3A) and Gd(DTPA-BMA). The 
bladder was visualized as a dark area with vague margins 
before the administration of the contrast agents. Strong 
signal intensities were observed in the bladder from 
2 minutes and throughout the period of experiments after 
the injection of nanoglobule-G4-cystamine-(Gd-DO3A) at 
0.033 mMol Gd/kg. The enhanced volume of the bladder 
gradually increased over time. The agent provided suffi-
cient contrast enhancement for MRI of the urinary systems 
that overcame the noise from the fat tissue and gut in the 
abdomen. In comparison, Gd(DTPA-BMA) at 0.1 mmol/kg 
could not result in clear visualization of the bladder. The 
bladder was barely visible at 5 and 10 minutes after the 
injection of Gd(DTPA-BMA). Strong bladder   enhancement 
was only observed at 15 minutes after administration, 
whereas the margin of the bladder was still vague. The 
low contrast enhancement in the bladder indicates low 
concentration of Gd(DTPA-BMA) in the urinary collect-
ing system, resulting in poor image qualities for anatomic 
urological diagnosis.
The functional information of renal excretion can be 
obtained from the DCE-MR images in ROIs in the urinary 
system. Figure 3 shows the 2D coronal images cross the 
kidneys. Both nanoglobule-G4-cystamine-(Gd-DO3A) and 
Gd(DTPA-BMA) resulted in significant contrast enhance-
ment in the kidneys. However, the contrast enhancement 
by Gd(DTPA-BMA) limited to the renal cortex in early 
minutes postinjection and gradually shifted into the renal International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Scheme 1 Synthesis of nanoglobule-G4-cystamine-(Gd-DO3A). (i) H2O, pH 9.0, 72 hours; (ii) gadolinium acetate, pH 5.0, 72 hours; EDTA, 1 hour.
pelvis, whereas the enhancement with   nanoglobule-G4-cys
tamine-(Gd-DO3A) mainly located in the renal pelvis since 
2 minutes postinjection, indicating faster renal excretion rate. 
The renal transit time, the time between the arrival of contrast 
materials in the cortex and its arrival in the ureter, is often 
used in scintigraphy to characterize diuretic renal function 
and to correlate to the washout half-life.31 Figure 3 clearly 
visualizes the shorter renal transit time of nanoglobule-G4-
cystamine-(Gd-DO3A). Figure 4 shows the time course of 
CNRs in the bladder. The nanoglobule-G4-cystamine-(Gd-
DO3A) resulted in much stronger signal intensities in the 
bladder at a much lower dose than Gd(DTPA-BMA) soon 
after the injection, validating faster renal elimination kinetics 
of nanoglobule-G4-cystamine-(Gd-DO3A).
Figure 5 displays the time courses of CNR in blood 
and the liver before and after the injection of the contrast 
agents. Nanoglobule-G4-cystamine-(Gd-DO3A) elimi-
nated from blood circulation at a relatively slower rate than 
  Gd(DTPA-BMA; Figure 5A). Nanoglobule-G4-cystamine-
(Gd-DO3A) resulted in higher contrast enhancement than 
Gd(DTPA-BMA) in the liver (Figure 5B). However, the 
difference of the CNRs between 2 agents in the liver was 
still in the same order of magnitude and much smaller than 
their CNR difference in the bladder (Figure 4). The results 
indicated that nanoglobule-G4-cystamine-(Gd-DO3A) 
extravasated slowly from blood circulation and had minimal 
nonspecific liver uptake. Therefore, majority of injected 
nanoglobule-G4-cystamine-(Gd-DO3A) excreted rapidly International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
711
A biodegradable nanosized MR contrast agent
via renal filtration, resulting in strong signal intensities in 
the kidneys and the urinary system.
Discussion
The nanoglobules, polylysine dendrimers with the cubic 
silsesquioxane core, has a compact and 3D symmetric 
molecular architecture and precisely defined nanosizes.25 
They may be advantageous over the conventional den-
drimers, such as PAMAM, as carriers for macromolecular 
MRI contrast agents. Although PAMAM dendrimers have 
precisely defined structures and sizes, and have been used 
as carriers for MRI contrast agents,32 their structure is still 
flexible and the contrast agents based on PAMAM have a 
highly positively charged interior structure, which may affect 
their in vivo biological properties. We have recently observed 
that a macromolecular contrast agent based on PAMAM, 
PAMAM-G6-(Gd-DO3A), had high liver uptake, and its cor-
responding biodegradable macromolecular agent, PAMAM-
G6-cystamine-(Gd-DO3A), resulted in death of experimental 
animal within 24 hours postadministration   possibly due to 
the systemic toxicity of the PAMAM dendrimer.24 The G1, 
G2, and G3 nanoglobular MRI contrast agents have neutral 
interior structure and have shown size-dependent in vivo 
contrast enhancement, minimal liver enhancement, and 
significant tumor enhancement in a mouse tumor model. 
They showed size-dependent renal filtration and elimination 
rate decreased with increasing size from G1 to G3 agents.26 
The G4 nanoglobule was chosen in this study as the carrier 
for the biodegradable nanoglobular contrast agents to take 
advantage of its high surface-loading capability.
Effective DCE-MR urography needs a sufficient amount 
of contrast agents passing through the urinary tract to be 
eliminated in urine in a relatively short timeframe. Low 
molecular weight MRI contrast agents rapidly extravasate 
into extracellular interstitium and, therefore, have a slow 
Pre 2 min 5 min 10 min 15 min
Figure 3 Contrast-enhanced coronal magnetic resonance images of nude mice 
before (pre) and at various time points after intravenous injection of nanoglobule-
G4-cystamine-(Gd-DO3A; top panel) and Gd(DTPA-BMA; lower panel). Arrows 
point to the kidney.
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Figure 1 T1 relaxivity of nanoglobule-G4-cystamine-(Gd-DO3A).
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Figure 2 Contrast-enhanced coronal magnetic resonance images of nude mice 
before (pre) and at various time points after intravenous injection of nanoglobule-
G4-cystamine-(Gd-DO3A; top panel) and Gd(DTPA-BMA; lower panel). Arrows 
point to the heart (1), liver (2), and bladder (3).
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Figure 4 Semilogarithmic plots of contrast-enhanced signal intensities in the bladder 
before and at various time points after the injection of () Gd(DTPA-BMA) and () 
nanoglobule-G4-cystamine-(Gd-DO3A; n = 3, Student’s t-test, **P , 0.002).
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conjugate as fast as 2 minutes   postadministration. The 
G4 biodegradable nanoglobular contrast agent also 
  demonstrated faster renal excretion kinetics than low 
molecular weight Gd(DTPA-BMA). Since Gd(III) chelates 
of the biodegradable nanoglobular contrast agent can be 
rapidly excreted via renal filtration, it may minimize tis-
sue Gd(III) accumulation of the agent. Since the size of 
the nanoglobular agent is smaller than the renal filtration 
threshold (8 nm),33 the remaining nanoglobules can be 
gradually excreted via renal filtration. The biodegradable 
nanoglobular contrast agent is promising for further devel-
opment for clinical MR urography.
This is the first attempt to develop biodegradable 
nanoglobular contrast agents with fast renal elimination 
for   effective DCE-MR urography. The study is limited in 
several areas. The conjugation efficiency of Gd-DO3A to 
the surface of nanoglobules was relatively low in the agent. 
Further   optimization is needed to increase the conjuga-
tion efficiency on the agent. The elimination mechanism 
of the biodegradable nanoglobular contrast agent needs to 
be   further elucidated to better understand the correlation 
of the elimination of the agent with renal functions and to 
  establish criteria for contrast-enhanced MR urography with 
the contrast agent. Further detailed preclinical studies, includ-
ing pharmacokinetics, biodistribution, and toxicity, of the 
agent and the clearance of G4 nanoglobule are needed before 
further consideration for clinical development.
Conclusion
In summary, the biodegradable nanoglobular MRI contrast 
agent, nanoglobule-G4-cystamine-(Gd-DO3A), was synthe-
sized for contrast-enhanced MR urography. The preliminary 
study has shown that the agent had faster elimination kinetics 
in the urinary tract than a low molecular weight clinical agent 
Gd(DTPA-BMA). The fast elimination kinetics is suitable for 
functional evaluation of the kidneys. The high concentration 
of the contrast agent in the urinary tract resulted in strong 
enhancement for effective morphological imaging of the 
tract with minimal noise from fluid in the abdomen. These 
features render nanoglobule-G4-cystamine-(Gd-DO3A) 
a suitable contrast agent for effective contrast-enhanced MR 
urography without diuretics.
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Figure 5 Contrast-enhanced signal intensities in the blood of left ventricle (A) and 
liver (B) before and at various time points after the injection of () Gd(DTPA-BMA) 
and () nanoglobule-G4-cystamine-(Gd-DO3A; n = 3, Student’s t-test, *P , 0.05). 
Abbreviation: CNR, contrast to noise ratio.
renal excretion rate. Macromolecular contrast agents 
generally have limited extravasation, but they also result 
in limited enhancement in the urinary tract because their 
large sizes lead to poor renal filtration. The conjugation of 
Gd(III)-DO3A chelates on the surface of the G4 nanoglobu-
lar carrier via the cleavable disulfide spacer substantially 
facilitate elimination of Gd(III)-chelate via renal filtration, 
resulting in significant dynamic enhancement in the urinary 
tract. The renal clearance of Gd-DO3A chelates from the 
nanoglobule-G4-cystamine-(Gd-DO3A) conjugate was 
faster than the nondegradable G2 and G3 nanoglobule-
(Gd-DO3A) conjugates of smaller sizes.26 The cleavage 
disulfide spacer in the conjugate by the endogenous thiols 
in the plasma resulted in fast blood-pool clearance, less 
liver deposit, and enhanced renal filtration of Gd(III) 
  chelates. As a result, strong   enhancement was shown in the 
urinary tract with nanoglobule-G4-cystamine-(Gd-DO3A) International Journal of Nanomedicine
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